Literature DB >> 20370550

Global impact of rotavirus vaccines.

Jacqueline E Tate1, Manish M Patel, A Duncan Steele, Jon R Gentsch, Daniel C Payne, Margaret M Cortese, Osamu Nakagomi, Nigel A Cunliffe, Baoming Jiang, Kathleen M Neuzil, Lucia H de Oliveira, Roger I Glass, Umesh D Parashar.   

Abstract

The WHO has recently recommended the inclusion of rotavirus vaccine in the national immunization programs of all countries. In countries in the Americas, Europe and Australia that have adopted routine childhood immunization against rotavirus, significant reductions in the burden of severe childhood diarrhea have been observed. Besides protecting vaccinated children, disease rates also appear to be reduced in unvaccinated children, suggesting indirect benefits from vaccination (i.e., herd protection). Early clinical trial data from Africa and Asia are promising, and further efforts are needed to optimize the benefits of vaccination in developing countries where vaccines are likely to have their greatest impact.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20370550     DOI: 10.1586/erv.10.17

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  34 in total

1.  Protein-energy malnutrition alters IgA responses to rotavirus vaccination and infection but does not impair vaccine efficacy in mice.

Authors:  Elizabeth A Maier; Kristina J Weage; Marjorie M Guedes; Lee A Denson; Monica M McNeal; David I Bernstein; Sean R Moore
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

2.  Postdose 3 G1 serum neutralizing antibody as correlate of protection for pentavalent rotavirus vaccine.

Authors:  G Frank Liu; Darcy Hille; Susan S Kaplan; Michelle G Goveia
Journal:  Hum Vaccin Immunother       Date:  2017-08-24       Impact factor: 3.452

Review 3.  Rotavirus vaccines: update on global impact and future priorities.

Authors:  Catherine Yen; Jacqueline E Tate; Manish M Patel; Margaret M Cortese; Benjamin Lopman; Jessica Fleming; Kristen Lewis; Baoming Jiang; Jon Gentsch; Duncan Steele; Umesh D Parashar
Journal:  Hum Vaccin       Date:  2011-12-01

4.  Comparing cost-effectiveness results for a vaccine across different countries worldwide: what can we learn?

Authors:  Baudouin Standaert; Olivier Ethgen; Rachel Emerson; Maarten Postma; Josephine Mauskopf
Journal:  Adv Ther       Date:  2014-10-21       Impact factor: 3.845

5.  Complete genome sequence analysis of candidate human rotavirus vaccine strains RV3 and 116E.

Authors:  Christine M Rippinger; John T Patton; Sarah M McDonald
Journal:  Virology       Date:  2010-06-26       Impact factor: 3.616

6.  Evaluating strategies to improve rotavirus vaccine impact during the second year of life in Malawi.

Authors:  Virginia E Pitzer; Aisleen Bennett; Naor Bar-Zeev; Khuzwayo C Jere; Benjamin A Lopman; Joseph A Lewnard; Umesh D Parashar; Nigel A Cunliffe
Journal:  Sci Transl Med       Date:  2019-08-14       Impact factor: 17.956

7.  Burden and genotyping of rotavirus disease in the United Arab Emirates: a multicenter hospital-based surveillance.

Authors:  Mohammad Howidi; Ghazala Balhaj; Hakam Yaseen; Kusuma Gopala; Leen Jan Van Doorn; Rodrigo DeAntonio
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 8.  Global Impact of Rotavirus Vaccination on Childhood Hospitalizations and Mortality From Diarrhea.

Authors:  Eleanor Burnett; Christine L Jonesteller; Jacqueline E Tate; Catherine Yen; Umesh D Parashar
Journal:  J Infect Dis       Date:  2017-06-01       Impact factor: 5.226

9.  Rotavirus gastroenteritis in children less than five years of age in primary care settings in Bulgaria: an observational study.

Authors:  Mayda Tiholova; Kusuma Gopala; Magda Berberova; Margarita Strokova-Stoilova; Monica Tafalla
Journal:  Germs       Date:  2016-09-01

10.  Virulence-associated genome mutations of murine rotavirus identified by alternating serial passages in mice and cell cultures.

Authors:  Takeshi Tsugawa; Masatoshi Tatsumi; Hiroyuki Tsutsumi
Journal:  J Virol       Date:  2014-03-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.